, , , , , , ,

More of the b/s we have come to love and expect from S&N…..

Smith & Nephew Voluntarily Withdraws Hip Component | Qmed.

LONDON, June 1, 2012 /PRNewswire/ — Smith & Nephew (LSE: SN; NYSE: SNN), the global medical technology business, has decided to initiate a voluntary market withdrawal of the optional metal liner component of its R3* Acetabular System. This does not impact other R3 System liners.

This action does not change the current practice for patient follow-up care for this component.

Andy Weymann MD, Smith & Nephew’s Chief Medical Officer, said: “We regularly review the effectiveness of our products and are not satisfied with the clinical results of this component. As with all medical devices, anyone experiencing unusual symptoms should contact their surgeon.”

Approximately 7,700 metal liners have been implanted since the component was introduced in 2007 and launched globally in 2009. The majority of these have been used in stemmed total hip replacements.

In 2011, procedures using this component accounted for less than 1% of Smith & Nephew’s global hip implant revenue.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).